Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups

Andishe Attarbaschi, Maria Morak, Gunnar Cario, Giovanni Cazzaniga, Hannah M. Ensor, Truus Te Kronnie, Jutta Bradtke, Georg Mann, Elena Vendramini, Chiara Palmi, Claire Schwab, Lisa J. Russell, Martin Schrappe, Valentino Conter, Christopher D. Mitchell, Sabine Strehl, Martin Zimmermann, Ulrike Pötschger, Christine J. Harrison, Martin StanullaRenate Panzer-grümayer, Oskar A. Haas, Anthony V. Moorman

Research output: Contribution to journalArticlepeer-review

Abstract

The prognostic relevance of CRLF2 -rearrangements in childhood acute B-cell precursor lymphoblastic leukaemia (ALL), was assessed by a comparative analysis of 114 non-Down-syndrome patients (99 P2RY8-CRLF2+ , 15 IGH@-CRLF2+ ), 76 from the AIEOP-BFM ALL 2000 and 38 from the MRC ALL97 trials. The 6-year cumulative relapse incidence of P2RY8-CRLF2+ patients treated on the two trials was not statistically different: 0·37 ± 0·06 vs. 0·25 ± 0·08 (P = 0·194). In contrast, 0/9 IGH@-CRLF2+ AIEOP-BFM, but 5/6 ALL97 patients relapsed. Conclusively, P2RY8-CRLF2+ patients had an intermediate protocol-independent outcome while the different prognosis of IGH@-CRLF2+ patients could be related to the different structures of the applied treatment protocols.
Original languageEnglish
Pages (from-to)772-777
JournalBritish journal of haematology
Volume158
Issue number6
DOIs
Publication statusPublished - 1 Sept 2012

Fingerprint

Dive into the research topics of 'Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups'. Together they form a unique fingerprint.

Cite this